Table 1.
Characteristics of anticancer drug in the NRDLN policy intervention group and comparison group.
| Category | Code | Generic name | Dosage form and strength | Indications | Market approval date on NMPA# |
|---|---|---|---|---|---|
| Intervention group | L01XC02▲ | Rituximab | 100 mg/10 mL, 500 mg/50 mL (Inj) | Non-Hodgkin’s lymphoma (NHL) | April 2000 |
| L01XC03▲ | Trastuzumab | 440 mg/20 mL (Inj) | Breast cancer, and gastric cancer | September 2002 | |
| L01XC07▲ | Bevacizumab | 100 mg/4 mL (Inj) | Colorectal cancer, and Non-small-cell lung cancer (NSCLC) | February 2010 | |
| XL01XC* | Nimotuzumab | 50 mg/10 mL (Inj) | Nasopharyngeal carcinoma (NPC) | April 2008 | |
| L01XE03▲ | Erlotinib | 150 mg, 100 mg (Tab) | NSCLC | April 2006 | |
| L01XE05▲ | Sorafenib | 200 mg (Tab) | Renal cell carcinoma, hepatocellular carcinoma (HCC), and thyroid carcinoma | September 2006 | |
| L01XE07▲ | Apatinib | 250 mg, 375 mg, 425 mg (Tab) | Gastric adenocarcinoma | October 2014 | |
| L01XE07▲ | Lapatinib | 250 mg (Tab) | Breast cancer | January 2013 | |
| L01XX32▲ | Bortezomib | 3.5 mg, 1 mg (Inj) | Multiple myeloma (MM), and lymphoma | February 2005 | |
| L02BA03▲ | Fulvestran | 250 mg/5 mL (Inj) | Breast cancer | January 2010 | |
| L02BX03▲ | Abiraterone | 250 mg (Tab) | Prostatic cancer | May 2015 | |
| L04AA18▲ | Everolimus | 5 mg, 2.5 mg (Tab) | Renal cell carcinoma, endocrine neoplasia, and angiomyolipoma (AML) | January 2013 | |
| L04AX04▲ | Lenalidomide | 10 mg, 25 mg (Tab) | MM | January 2013 | |
| XL01XX* | Chidamide | 5 mg (Tab) | Peripheral T cell lymphomas (PTCL) | December 2014 | |
| XL01XX* | Recombinant human endostatin | 15 mg/2.4 × 105 U/3 mL (Inj) | NSCLC | September 2005 | |
| ZC01* | Compound realga natural indigo tablets | 270 mg (Tab) | Acute promyelocytic leukemia (APL) | July 2009 | |
| ZC02* | Astragalus polysaccharide for injection | 250 mg (Inj) | Antineoplastic adjuvant drugs | August 2004 | |
| ZC02* | Shenyi capsule | 10 mg (Cap) | Antineoplastic adjuvant drugs | April 2003 | |
| Comparison group | L01XC06▲ | Cetuximab | 100 mg/20 ml inj | Colorectal cancer | July 2006 |
| L01XE04▲ | Sunitinib | 12.5 mg cap | Kidney cancer; Stomach cancer; Pancreatic cancer | October 2007 | |
| L01XX24* | Pegaspargase | 5 mL:3750 IU inj | Leukemia | January 2009 | |
| L01XE08▲ | Nilotinib | 200 mg cap,150 mg cap | Leukemia | July 2009 | |
| L01XE16▲ | Crizotinib | 200 mg cap | Lung cancer | January 2013 | |
| L01XE17▲ | Axitinib | 5 mg tab,1 mg tab | Kidney cancer | April 2015 |
▲ATC Code from the WHO Collaborating Center for Drug Statistics Methodology. *Medicine classification and codes for basic medical insurance. #NMPA, National Medical Products Administration of China.